Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
about
A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigsCurrent status and prospects for development of an HSV vaccineBlocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivoPan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital modelA novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in miceImmunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigsA Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.The challenge of developing a herpes simplex virus 2 vaccine.An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention.Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responsesProtection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.A Herpes Simplex Virus Type 2 Deleted for Glycoprotein D Enables Dendritic Cells to Activate CD4+ and CD8+ T Cells.Development of Recombinant HSV-Based Vaccine Vectors.Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains.A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection
P2860
Q33825931-2AEE7D6D-D738-495A-836F-FE5259D2662AQ33931016-EF2FED3E-2BB4-41A7-87BD-095C286A0704Q34057952-4EE07036-59F9-4250-8502-AAD0E6F7B387Q34331569-A2D01C32-870C-4290-AD24-A519804EA9D0Q34350019-530D7222-4FCD-402A-979C-90304F91EF56Q34414463-09041EA4-841B-401A-B75B-DE50B874D546Q34447379-DA503210-8C84-4A72-90AC-A3FB08531A0FQ35009410-29F24C86-8AB9-4053-AB14-D448D388C969Q35249684-41AD5E20-F151-423C-AFC4-ACF537D313F6Q36433844-03DEFC0C-E994-4D3E-BB1F-AF6F21EC2651Q36671106-9E9FE6BA-80C2-4FD3-978E-E9A848DE3A8DQ36759693-FEB6CA00-B6F1-4F9E-885B-365D974F8189Q36765590-264D1CEC-4F0B-4B4D-BF00-B4078AF71CDAQ36824210-875362FD-E492-4169-A24A-9020C40924CCQ37125722-38B17080-8173-475C-AC9C-6C3ACB54E5D8Q37305004-F6291CA8-801E-46A4-B781-781C50D39580Q37547107-61D4EBA3-6C86-4042-AF04-AFA988AB9209Q37611796-70996514-C09E-4ED7-84A0-090BCE6C6F77Q38212516-026468F0-F88B-4D22-9DEB-FB4D55605B4BQ38241377-D2181F87-EE4E-4E25-98DB-D1E52323E38FQ40067153-C051A7D0-4AF9-480E-B2E6-BE9788C59FF0Q40259646-0243CE65-7D4F-4717-8BAC-11EEA5ECD017Q45325692-0A8F6D65-2A99-4F4A-89B8-0F31B95B2885Q57072187-D52E083E-5A07-4B64-87B6-EEC167AA5453
P2860
Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Live attenuated herpes simplex ...... defective in neuronal spread.
@ast
Live attenuated herpes simplex ...... defective in neuronal spread.
@en
type
label
Live attenuated herpes simplex ...... defective in neuronal spread.
@ast
Live attenuated herpes simplex ...... defective in neuronal spread.
@en
prefLabel
Live attenuated herpes simplex ...... defective in neuronal spread.
@ast
Live attenuated herpes simplex ...... defective in neuronal spread.
@en
P2093
P2860
P356
P1433
P1476
Live attenuated herpes simplex ...... defective in neuronal spread.
@en
P2093
Carolyn E Shaw
Danilo R Casimiro
Elizabeth E Zumbrun
Fushan Wang
Harvey M Friedman
Janine T Bryan
Jessica A Flynn
John M Lubinski
John W Balliet
P2860
P304
P356
10.1128/JVI.07203-11
P407
P577
2012-02-08T00:00:00Z